A Controlled Trial of Erenumab in Migraine Prevention

Inclusion Criteria

• •Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.
• •Japanese subjects greater than or equal to 20 to less than or equal to 65 years of age upon entry into screening.
• •History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the International Headache Society Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018) based on medical records and/or patient self-report
• •Migraine frequency: Chronic Migraine (CM) or Episodic Migraine (EM) over the 3 months before screening based on the following criteria:
• •1. CM is defined as greater than or equal to 15 headache days per month of which greater than or equal to 8 headache days on average across the 3 months meet criteria as migraine days
• •2. EM is defined as less than 15 headache days per month of which at least 4 or more headache days on average across the 3 months meet criteria as migraine days